Abstract:Background: One reason patients with cancer cannot benefit from immunotherapy is the lack of immune cell infiltration in tumor tissues. Cancer-associated fibroblasts (CAFs) are emerging as central players in immune regulation that shapes tumor microenvironment (TME). Earlier we reported that integrin α5 was enriched in CAFs in colorectal cancer (CRC), however, its role in TME and cancer immunotherapy remains unclear. Here, we aimed to investigate the role for integrin α5 in fibroblasts in modulating antitumor immunity and therapeutic efficacy combined with checkpoint blockade in CRC. Methods: We analyzed the CRC single-cell RNA sequencing (scRNA-seq) database to define the expression of ITGA5 in CRC tumor stroma. Experimentally, we carried out in vivo mouse tumor xenograft models to confirm the targeting efficacy of combined α5β1 inhibition and anti-Programmed death ligand 1 (PD-L1) blockade and in vitro cell-co-culture assay to investigate the role of α5 in fibroblasts in affecting T-cell activity. Clinically, we analyzed the association between α5 expression and infiltrating T cells and evaluated their correlation with patient survival and immunotherapy prognosis in CRC. Results: We revealed that ITGA5 was enriched in FAP-CAFs. Both ITGA5 knockout fibroblasts and therapeutic targeting of α5 improved response to anti-PD-L1 treatment in mouse subcutaneous tumor models. Mechanistically, these treatments led to increased tumor-infiltrating CD8+ T cells. Furthermore, we found that α5 in fibroblasts correlated with extracellular matrix (ECM)-related genes and affected ECM deposition in CRC tumor stroma. Both in vivo analysis and in vitro culture and cell killing experiment showed that ECM proteins and α5 expression in fibroblasts influence T-cell infiltration and activity. Clinically, we confirmed that high α5 expression was associated with fewer CD3+ T and CD8+ T cells, and tissues with low α5 and high CD3+ T levels correlated with better patient survival and immunotherapy response in a CRC cohort with 29 patients. Conclusions: Our study identified a role for integrin α5 in fibroblasts in modulating antitumor immunity by affecting ECM deposition and showed therapeutic efficacy for combined α5β1 inhibition and PD-L1 blockade in CRC.

Integrin β5 enhances the malignancy of human colorectal cancer by increasing the TGF-β signaling

High Expression of UNC5B Enhances Tumor Proliferation, Increases Metastasis, and Worsens Prognosis in Breast Cancer.

ITGB5 facilitates gastric cancer metastasis by promoting TGFBR2 endosomal recycling

Integrin β5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis and immunotherapy efficacy in gastric cancer

ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors

TGFBI Protein High Expression Predicts Poor Prognosis in Colorectal Cancer Patients.

ITGBL1 promotes migration, invasion and predicts a poor prognosis in colorectal cancer

Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition

Integrin Beta 5 Is a Prognostic Biomarker and Potential Therapeutic Target in Glioblastoma

ROS-mediated ITGB5 promotes tongue squamous cell carcinoma metastasis through epithelial mesenchymal transition and cell adhesion signal pathway

ITGA5 Promotes Tumor Progression through the Activation of the FAK/AKT Signaling Pathway in Human Gastric Cancer

Gdf15 Promotes Emt And Metastasis In Colorectal Cancer

Ets Variant 5 Promotes Colorectal Cancer Angiogenesis By Targeting Platelet-Derived Growth Factor Bb

IGFBP5 is Upregulated and Associated with Poor Prognosis in Colorectal Cancer

METTL5 promotes cell proliferation, invasion, and migration by up-regulating Toll-like receptor 8 expression in colorectal cancer

ITGBL1 promotes cell migration and invasion through stimulating the TGF‐β signalling pathway in hepatocellular carcinoma

ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas

TGF-β1 Modulated the Expression of Α5β1 Integrin and Integrin-Mediated Signaling in Human Hepatocarcinoma Cells

ITGA5 promotes tumor angiogenesis in cervical cancer

Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells

The role of E26 transformation-specific variant transcription factor 5 in colorectal cancer cell proliferation and cell cycle progression